<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04384627</url>
  </required_header>
  <id_info>
    <org_study_id>5010-2019-09</org_study_id>
    <nct_id>NCT04384627</nct_id>
  </id_info>
  <brief_title>Reducing Target Volumes in NPC Treated With Induction Chemotherapy Followed by Concurrent Chemoradiotherapy</brief_title>
  <acronym>NPC-GTV</acronym>
  <official_title>Reducing Target Volumes in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma Treated With Induction Chemotherapy Followed by Concurrent Chemoradiotherapy: A Phase 3, Multicentre, Non-inferiority, Randomised Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>First People's Hospital of Foshan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Guilin Medical College</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the long-term locoregional control, survival rate, late toxicity and quality of
      life after reducing the target volume in patients with locoregionally advanced nasopharyngeal
      carcinoma patients treated with induction chemotherapy plus concurrent chemoradiotherapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This phase 3, multicenter, non-inferiority, randomized controlled clinical trial recruits
      patients with newly-diagnosed locoregionally advanced nasopharyngeal carcinoma patients
      treated with induction chemotherapy plus concurrent chemoradiotherapy. The intervention is
      delineating the gross tumor volume according to pretreatment tumor extension (the pre-IC GTV
      group) or post-induction chemotherapy tumor extension (the post-IC GTV group). The objective
      is to compare the long-term locoregional control, survival rate, late toxicity and quality of
      life between the two groups.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 1, 2019</start_date>
  <completion_date type="Anticipated">October 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Multicentre, Non-inferiority, Randomised controlled trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Relapse-free survival of the patients</measure>
    <time_frame>3 year</time_frame>
    <description>the time from randomization to documented locoregional recurrence or death from any cause, whichever occurred first</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival of the patients</measure>
    <time_frame>3 year</time_frame>
    <description>the time from randomization to documented death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Late toxicities</measure>
    <time_frame>3 months</time_frame>
    <description>Occur 3 months after IMRT, graded according to the Radiation Therapy Oncology Group radiation morbidity scoring criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional Assessment of Cancer Therapy-Head and Neck questionnaire</measure>
    <time_frame>3 year</time_frame>
    <description>Patient-reported QoL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional Assessment of Chronic Illness Therapy-Fatigue questionnaire</measure>
    <time_frame>3 year</time_frame>
    <description>Patient-reported QoL</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">347</enrollment>
  <condition>Nasopharyngeal Carcinoma</condition>
  <condition>Induction Chemotherapy</condition>
  <condition>Radiotherapy</condition>
  <arm_group>
    <arm_group_label>Pre-IC GTV</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The gross tumor volume (GTV) is delineated according to the pretreatment tumor extension</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Post-IC GTV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The gross tumor volume (GTV) is delineated according to the post-IC tumor extension</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Delineating the GTV according to the pretreatment or post-IC tumor extension</intervention_name>
    <description>Delineating the GTV according to the pretreatment or post-IC tumor extension</description>
    <arm_group_label>Post-IC GTV</arm_group_label>
    <arm_group_label>Pre-IC GTV</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  histologic confirmation of nonkeratinizing nasopharyngeal carcinoma; no previous
             treatment for cancer; nondistant metastatic, newly diagnosed stage III to IVa disease
             that was staged according to the American Joint Committee on Cancer-Union for
             International Cancer Control 8th edition stage-classification system15; a Karnofsky
             performance-status score of at least 70 (on a scale from 0 to 100, with lower scores
             indicating greater disability); planned to recieve 2-3 cycles of gemcitabine and
             cisplatin Induction Chemotherapy; and adequate hematologic, renal, and hepatic
             function.

        Exclusion Criteria:

          -  younger than 18 years or elder than 70 years; receipt of treatment with palliative
             intent; a history of cancer; receipt of previous treatment (radiotherapy,
             chemotherapy, or surgery [except diagnostic procedures]) to the nasopharynx or neck;
             lactation or pregnancy; or severe coexisting illness; had disease progress after IC
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ling-Long Tang</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sun Yat-sen University Cancer Centr</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>First People's Hospital of Foshan, Foshan</name>
      <address>
        <city>Foshan</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guilin Medical College</name>
      <address>
        <city>Guilin</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Zhang Y, Chen L, Hu GQ, Zhang N, Zhu XD, Yang KY, Jin F, Shi M, Chen YP, Hu WH, Cheng ZB, Wang SY, Tian Y, Wang XC, Sun Y, Li JG, Li WF, Li YH, Tang LL, Mao YP, Zhou GQ, Sun R, Liu X, Guo R, Long GX, Liang SQ, Li L, Huang J, Long JH, Zang J, Liu QD, Zou L, Su QF, Zheng BM, Xiao Y, Guo Y, Han F, Mo HY, Lv JW, Du XJ, Xu C, Liu N, Li YQ, Chua MLK, Xie FY, Sun Y, Ma J. Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma. N Engl J Med. 2019 Sep 19;381(12):1124-1135. doi: 10.1056/NEJMoa1905287. Epub 2019 May 31.</citation>
    <PMID>31150573</PMID>
  </results_reference>
  <results_reference>
    <citation>Sun Y, Li WF, Chen NY, Zhang N, Hu GQ, Xie FY, Sun Y, Chen XZ, Li JG, Zhu XD, Hu CS, Xu XY, Chen YY, Hu WH, Guo L, Mo HY, Chen L, Mao YP, Sun R, Ai P, Liang SB, Long GX, Zheng BM, Feng XL, Gong XC, Li L, Shen CY, Xu JY, Guo Y, Chen YM, Zhang F, Lin L, Tang LL, Liu MZ, Ma J. Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial. Lancet Oncol. 2016 Nov;17(11):1509-1520. doi: 10.1016/S1470-2045(16)30410-7. Epub 2016 Sep 27.</citation>
    <PMID>27686945</PMID>
  </results_reference>
  <results_reference>
    <citation>Zhao C, Miao JJ, Hua YJ, Wang L, Han F, Lu LX, Xiao WW, Wu HJ, Zhu MY, Huang SM, Lin CG, Deng XW, Xie CH. Locoregional Control and Mild Late Toxicity After Reducing Target Volumes and Radiation Doses in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma Treated With Induction Chemotherapy (IC) Followed by Concurrent Chemoradiotherapy: 10-Year Results of a Phase 2 Study. Int J Radiat Oncol Biol Phys. 2019 Jul 15;104(4):836-844. doi: 10.1016/j.ijrobp.2019.03.043. Epub 2019 Apr 5.</citation>
    <PMID>30954521</PMID>
  </results_reference>
  <results_reference>
    <citation>Yang H, Chen X, Lin S, Rong J, Yang M, Wen Q, Shang C, He L, Ren P, Xu S, Zhang J, Liu Q, Pang H, Shi X, Fan J, Sun X, Ma D, Tan B, Zhang T, Zhang L, Hu D, Du X, Zhang Y, Wen S, Zhang X, Wu J. Treatment outcomes after reduction of the target volume of intensity-modulated radiotherapy following induction chemotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: A prospective, multi-center, randomized clinical trial. Radiother Oncol. 2018 Jan;126(1):37-42. doi: 10.1016/j.radonc.2017.07.020. Epub 2017 Aug 29.</citation>
    <PMID>28864073</PMID>
  </results_reference>
  <results_reference>
    <citation>McDowell LJ, Rock K, Xu W, Chan B, Waldron J, Lu L, Ezzat S, Pothier D, Bernstein LJ, So N, Huang SH, Giuliani M, Hope A, O'Sullivan B, Bratman SV, Cho J, Kim J, Jang R, Bayley A, Ringash J. Long-Term Late Toxicity, Quality of Life, and Emotional Distress in Patients With Nasopharyngeal Carcinoma Treated With Intensity Modulated Radiation Therapy. Int J Radiat Oncol Biol Phys. 2018 Oct 1;102(2):340-352. doi: 10.1016/j.ijrobp.2018.05.060. Epub 2018 Jun 4.</citation>
    <PMID>30191868</PMID>
  </results_reference>
  <results_reference>
    <citation>Sommat K, Ong WS, Hussain A, Soong YL, Tan T, Wee J, Fong KW. Thyroid V40 Predicts Primary Hypothyroidism After Intensity Modulated Radiation Therapy for Nasopharyngeal Carcinoma. Int J Radiat Oncol Biol Phys. 2017 Jul 1;98(3):574-580. doi: 10.1016/j.ijrobp.2017.03.007. Epub 2017 Mar 14.</citation>
    <PMID>28581397</PMID>
  </results_reference>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 8, 2020</study_first_submitted>
  <study_first_submitted_qc>May 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 12, 2020</study_first_posted>
  <last_update_submitted>May 11, 2020</last_update_submitted>
  <last_update_submitted_qc>May 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Ling-Long Tang</investigator_full_name>
    <investigator_title>M.D.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Nasopharyngeal Carcinoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

